Article By:
BioMedReports
Thursday, October 9, 2014 3:03 AM EDT
Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform, might one day join the leagueof bigger players.